ImmuneOncia Therapeutics has entered a manufacturing agreement with Swiss contract drugmaker Lonza to support late‑stage clinical production of Danburstotug, an experimental monoclonal antibody targeting PD‑L1 for relapsed or refractory NK/T‑cell lymphoma.

Under the deal, Lonza will produce drug substance at its Slough, U.K., facility, while drug‑product development and clinical manufacturing will occur at sites in Basel and Stein, Switzerland. The South Korea–based biotech said it is leveraging Lonza’s end‑to‑end development and manufacturing capabilities as it positions the therapy for late‑stage clinical readiness and potential commercial rollout.

ImmuneOncia CEO Heung‑Tae Kim said the company aims to seek early approval in the rare lymphoma indication, adding that the Lonza collaboration strengthens the program’s global commercial prospects. Lonza executive Michael de Marco said the partnership reflects the CDMO’s strategy of supporting emerging biotechs through manufacturing scale‑up and eventual commercialization.